<!--Enhanced HTML document created with Toppan Merrill Bridge  9.6.2.57--><!--Created on: 6/26/2020 08:07:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-transform:none;white-space:pre-wrap;">Washington, D.C.  20549</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 6pt 0pt;"><b style="font-size:18pt;font-weight:bold;">FORM 8-K</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-weight:bold;text-transform:none;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): June 23, 2020</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-size:20pt;font-weight:bold;">RESHAPE LIFESCIENCES INC.</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Exact name of registrant as specified in its charter)</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;table-layout:auto;width:102.3%;"><tr><td style="vertical-align:top;width:33.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></td><td colspan="2" style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1-33818</b></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">48-1293684</b></p></td></tr><tr><td style="vertical-align:top;width:33.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">of incorporation)</p></td><td colspan="2" style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Commission </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:33.14%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1001 Calle Amanecer</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">San Clemente, CA </b></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">92673</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table></div><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-weight:bold;">(949) 429-6680</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><font style="text-transform:none;">(Registrant&#8217;s telephone number, including area code)</font></p><p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt;"><b style="font-weight:bold;text-transform:none;">Not applicable</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Former name or former address, if changed since last report.)</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<font style="display:inline-block;width:7.43pt;"></font><font style="display:inline-block;width:36pt;"></font></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="font-family:'Wingdings';font-size:12pt;">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;"><a name="Check1"></a></font><font style="font-family:'Wingdings';font-size:12pt;">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt;"><font style="font-family:'Wingdings';font-size:12pt;">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Wingdings';font-size:12pt;">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;width:100%;"><tr><td style="vertical-align:middle;width:39.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">Title of each class</font></p></td><td style="vertical-align:middle;width:19.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">Trading Symbol(s)</font></p></td><td style="vertical-align:middle;width:41.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">Name of each exchange on which registered</font></p></td></tr><tr><td style="vertical-align:middle;width:39.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">Common stock, $0.001 par value per share</font></p></td><td style="vertical-align:middle;width:19.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">RSLS</font></p></td><td style="vertical-align:middle;width:41.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Calibri';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman';">OTCQB Market</font></p></td></tr></table></div><p style="font-family:'Times New Roman';font-size:10pt;margin:6pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Emerging growth company&#160;<font style="font-family:'Wingdings';font-size:12pt;">o</font> </p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;<font style="font-family:'Wingdings';font-size:12pt;">o</font></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><b style="border-bottom-style:solid;border-bottom-width:0.5pt;font-size:14pt;font-weight:bold;text-decoration:underline;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></b><font style="font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><a name="PARA228_2"></a><b style="font-size:11pt;font-weight:bold;">Item 2.03</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:11pt;margin:0pt;">As previously disclosed, on March 25, 2020, ReShape Lifesciences Inc. (the &#8220;Company&#8221;) entered into a Credit Agreement (as amended from time to time, the &#8220;Credit Agreement&#8221;) with Armistice Capital Master Fund Ltd. (the &#8220;Lender&#8221;), pursuant to which the Company borrowed the initial principal amount of $2.5 million, with the option to borrow up to an additional $1.0 million pursuant to delayed draw term loans. A copy of the Credit Agreement was filed as an exhibit to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2020.</p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:11pt;margin:0pt;">On June 23, 2020, the Company borrowed an additional $0.5 million available under the Credit Agreement pursuant to a delayed draw term loan. The maturity date of the loan is September 24, 2020, and the interest rate is equal to the LIBOR rate plus 2.5%. As a result of this drawdown, the Company has an outstanding principal balance of $3.0 million under the Credit Agreement and has the option to borrow up to an additional $0.5&#160;million pursuant to one additional delayed draw term loan. The proceeds from the loan will be available for general corporate purposes, including working capital. </p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"><a name="PARA119"></a></font><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:11pt;text-indent:39.6pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.<font style="font-size:12pt;"><a name="PARA141"></a></font></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:39.6pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:39.6pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:32.4pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">RESHAPE LIFESCIENCES INC.</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:39.6pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">By:</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:20.11pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">/s/ </u><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;text-transform:uppercase;">thomas stankovich</u><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:10.16pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:277.7pt;"></font><font style="font-size:11pt;">T</font><b style="font-size:11pt;font-weight:bold;">homas Stankovich</b></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:267.15pt;"></font><font style="font-size:11pt;">Senior Vice President and</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:272.79pt;"></font><font style="font-size:11pt;">Chief Financial Officer</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:229.42pt;"></font><font style="font-size:11pt;">(principal financial and accounting officer)</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:229.5pt;"></font><font style="font-size:11pt;"> </font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman';font-size:11pt;margin:0pt;">Dated: June 26, 2020</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:9.41%;margin-right:9.41%;margin-top:30pt;page-break-after:avoid;width:81.18%;border-width:0;"></body></html>
[{"type": "8-K", "sequence": "1", "filename": "tmb-20200623x8k.htm", "description": "8-K", "secsgml_size_bytes": 31552}]
{"company-data": {"conformed-name": "ReShape Lifesciences Inc.", "cik": "0001371217", "assigned-sic": "3845", "irs-number": "481293684", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33818", "film-number": "20994203"}, "business-address": {"street1": "1001 CALLE AMANECER", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673", "phone": "9494296680"}, "mail-address": {"street1": "1001 CALLE AMANECER", "city": "SAN CLEMENTE", "state": "CA", "zip": "92673"}, "former-company": {"former-conformed-name": "EnteroMedics Inc", "date-changed": "20060802"}}
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported): June 23, 2020
RESHAPE LIFESCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware
1-33818
48-1293684
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
​
​
1001 Calle Amanecer
San Clemente, CA
​
92673
(Address of principal executive offices)
(Zip Code)
​
(949) 429-6680
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.001 par value per share
RSLS
OTCQB Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​ ​
​
​
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
.
​
As previously disclosed, on March 25, 2020, ReShape Lifesciences Inc. (the "Company") entered into a Credit Agreement (as amended from time to time, the "Credit Agreement") with Armistice Capital Master Fund Ltd. (the "Lender"), pursuant to which the Company borrowed the initial principal amount of $2.5 million, with the option to borrow up to an additional $1.0 million pursuant to delayed draw term loans. A copy of the Credit Agreement was filed as an exhibit to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31, 2020.
​
On June 23, 2020, the Company borrowed an additional $0.5 million available under the Credit Agreement pursuant to a delayed draw term loan. The maturity date of the loan is September 24, 2020, and the interest rate is equal to the LIBOR rate plus 2.5%. As a result of this drawdown, the Company has an outstanding principal balance of $3.0 million under the Credit Agreement and has the option to borrow up to an additional $0.5 million pursuant to one additional delayed draw term loan. The proceeds from the loan will be available for general corporate purposes, including working capital.
​
SIGNATURES
​
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
RESHAPE LIFESCIENCES INC.
​
​
By:
​ ​
/s/
thomas stankovich
​ ​
​ ​
T
homas Stankovich
Senior Vice President and
Chief Financial Officer
(principal financial and accounting officer)
​
​
Dated: June 26, 2020
​